Press release
Postpartum Depression Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Postpartum Depression Pipeline. Dive into DelveInsight's comprehensive report today! @ Postpartum Depression Pipeline Outlook [https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Postpartum Depression Pipeline Report
* In March 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
* DelveInsight's Postpartum Depression pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Diabetes treatment.
* The leading Postpartum Depression Companies such as GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
* Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO Registered and others.
Stay ahead with the most recent pipeline outlook for Postpartum Depression. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Postpartum Depression Treatment Drugs [https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Postpartum Depression Emerging Drugs Profile
* RE-104: Reunion Neuroscience
RE104 is a proprietary, potential best-in-class, serotonergic neuroplastogen. RE-104 is designed as a single-dose psychedelic that offers a fast onset and shorter treatment duration, as well as reproducible pharmacokinetics. It has potential across a variety of neuropsychiatric indications, including in PPD and AjD, where Reunion is focusing its initial clinical development efforts. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Postpartum Depression.
* GH001: GH Research
GH001 is an inhaled formulation of mebufotenin (5-MeO-DMT), a psychedelic compound that acts as a potent serotonin 5-HT1A and 5-HT2A receptor agonist. By rapidly modulating serotonergic signaling, GH001 is believed to induce profound and short-lasting psychoactive effects, which may help reset dysfunctional neural circuits implicated in mood disorders. It is being investigated for treatment-resistant depression (TRD), bipolar II disorder, and postpartum depression.
* BRII-297: Brii Bio
BRII-297 is a first-of-its-kind long-acting injectable (LAI) therapeutic candidate in development for the treatment of various anxiety and depressive disorders. Discovered internally, BRII-297 acts as a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator (PAM), a proven mechanism of action that is known to potentially restore "normal" levels GABAA receptor function for various depressive and anxiety central nervous system disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of postpartum depression.
The Postpartum Depression Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Postpartum Depression with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression Treatment.
* Postpartum Depression Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Postpartum Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Postpartum Depression market
Explore groundbreaking therapies and clinical trials in the Postpartum Depression Pipeline. Access DelveInsight's detailed report now! @ New Postpartum Depression Drugs [https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Postpartum Depression Companies
GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
Postpartum Depression Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Postpartum Depression Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Postpartum Depression Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Postpartum Depression Market Drivers and Barriers [https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Postpartum Depression Pipeline Report
* Coverage- Global
* Postpartum Depression Companies- GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
* Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO Registered and others.
* Postpartum Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Postpartum Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Postpartum Depression Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Postpartum Depression Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Postpartum Depression: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Postpartum Depression - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Postpartum Depression Collaboration Deals
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* RE-104: Reunion Neuroscience
* Early Stage Products (Phase I)
* BRII-297: Brii Bio
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Postpartum Depression Key Companies
* Postpartum Depression Key Products
* Postpartum Depression- Unmet Needs
* Postpartum Depression- Market Drivers and Barriers
* Postpartum Depression- Future Perspectives and Conclusion
* Postpartum Depression Analyst Views
* Postpartum Depression Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=postpartum-depression-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Postpartum Depression Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3959426 • Views: …
More Releases from ABNewswire
Non-Small Cell Lung Cancer Market Positioned for Accelerated Development Through …
The Key Non-Small Cell Lung Cancer Companies in the market include - AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, AstraZeneca, Amgen, Blueprint Medicines/Rigel Pharmaceuticals, and others.
The Non-Small Cell Lung Cancer (NSCLC) market was valued at approximately USD 32 billion in 2025 and…
Vietnamese University Students Publish 'Vietnam Hangeul Newspaper' ... K-Wave No …
Image: https://www.abnewswire.com/upload/2025/10/fe9c4c1c8de543dfef7abbb9c8e22d9d.jpg
Vietnamese youth are attracting attention from Korea and around the world by producing a newspaper written entirely in Hangeul, the Korean alphabet. First launched online in January, the "Vietnam Hangeul Newspaper" is a regular publication created by students from six Vietnamese universities. While it is common for non-English-speaking countries to publish newspapers in English, this marks the world's first instance of local students voluntarily producing a newspaper in Hangeul.
Currently,…
From Culture Kings to Creator Army: Simon Beard Announces New AI Content Venture
Simon Beard, co-founder of Culture Kings, launches Creator Army-an AI-assisted content bootcamp and on-demand marketplace for creators.
Gold Coast, Australia - October 7, 2025 - Serial entrepreneur Simon Beard, best known as the founder of global streetwear retailer Culture Kings, this week announced the forthcoming launch of his latest venture, Creator Army-an AI-assisted content creation platform and on-demand marketplace built to empower the next generation of creators and help businesses access…
Experts Pick SendTurtle in Roundup of Best File Transfer Tools for Security-Cons …
Recognition highlights SendTurtle's unique blend of privacy-first design, AI analytics, and seamless user experience.
Arlington, VA - SendTurtle, the SaaS platform redefining how startups, consultants, and business leaders share documents, today announced that it has been recognized by industry experts in a recent roundup of the best file transfer tools for security-conscious teams. The acknowledgment underscores SendTurtle's rapid rise as the trusted platform for secure, frictionless file sharing with built-in intelligence.
Unlike…
More Releases for Postpartum
Postpartum Care Services Market 2025-2033
London, UK - September 2025 | Strategic Revenue Insights Inc. The Postpartum Care Services market is rapidly emerging as a critical sector within the global healthcare industry, driven by the increasing focus on maternal health and well-being. As families recognize the importance of comprehensive postpartum support, demand for specialized services such as in-home care, hospital-based care, telehealth, and lactation consulting has surged. Forecasts indicate that the market is poised to…
Key Trend Reshaping the Postpartum Depression Market in 2025: Companies Innovati …
What Are the Projections for the Size and Growth Rate of the Postpartum Depression Market?
The postpartum depression market has witnessed exponential growth in recent years. It will grow from $12.15 billion in 2024 to $16.09 billion in 2025, at a CAGR of 32.4%. The historic growth can be attributed to increased awareness about maternal mental health, research progress, public health initiatives, and a rise in screenings.
The postpartum depression market is…
Postpartum Depression Global Market Report 2024 - Postpartum Depression Market S …
The Business Research Company recently released a comprehensive report on the Global Postpartum Depression Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The postpartum depression market…
Elevate Your Strategy: Insights on Postpartum Depression Market Potential
𝐆𝐫𝐨𝐰𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬, a renowned Market research firm, introduces its latest research report on the 𝐏𝐨𝐬𝐭𝐩𝐚𝐫𝐭𝐮𝐦 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭, providing a detailed guide for businesses seeking growth progression. This report is meticulously crafted to aid in investment decisions, offering crucial insights and encouraging strategic investment discretion for new entrants aiming for seamless Market penetration.
𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐨𝐬𝐭𝐩𝐚𝐫𝐭𝐮𝐦 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐑𝐞𝐩𝐨𝐫𝐭 https://growthmarketreports.com/request-sample/4187
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐏𝐨𝐬𝐭𝐩𝐚𝐫𝐭𝐮𝐦 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭:
The global…
Postpartum Hemorrhage Treatment Market Trends | 2022 | Industry Analysis
The global postpartum hemorrhage treatment market size was valued at USD 802.34 in 2021, growing at a CAGR of 5.3% during the forecast period 2022-28. During the postpartum hemorrhage surgical operation, postpartum hemorrhage therapy devices are essential medical equipment. The severe blood loss that occurs in the initial few hours following childbirth is known as postpartum hemorrhage, and it can even result in the death of the mother. It is…
Demand: Postpartum Hemorrhage Devices Market to Fuel Revenue Growth
The global postpartum hemorrhage devices market is estimated to surpass $1,170.3 million by 2027, exhibiting a CAGR of 5.2% from 2020 to 2027.
The report aims to cater scrupulous analysis of the global postpartum hemorrhage devices market by methodically reviewing different facets of the market such as key segments, market dynamics, regional market circumstances, investment opportunities, and top players operating in the market.
In addition, the report offers insights on the current…
